Why Process Development Decisions Matter More Than Ever
A promising molecule is only the beginning of a successful drug development program. The real challenge lies in translating that science into a process that can consistently deliver quality material at the scale, speed, and cost required for clinical and commercial success.
As therapies become more complex and development timelines continue to compress, process development has become a strategic driver of program success. Decisions made during route selection, process optimization, impurity management, process safety evaluation, and scale-up planning directly influence a program’s ability to scale, fulfill regulatory expectations, and maintain reliable supply.
Process development decisions now carry unprecedented strategic weight across all pharmaceutical manufacturing dimensions simultaneously. Yield optimization directly drives profitability (1% improvement = 10-20% margin gain), while solvent and reagent selection can slash COGS significantly; simultaneously, early choices lock in supplier relationships and catalyst recovery economics, while directly impacting the ability to meet market demand through optimized capacity and throughput decisions.
Compressed timelines to FDA submission (18 months vs. 3-5 years historically), personalized medicine’s smaller batch requirements, geopolitical uncertainty forcing supply chain redundancy, and relentless cost-reduction pressures (50% COGS targets to compete with biosimilars) mean every process chemistry decision—from catalyst system to solvent choice to scale-up route—cascades across economics, compliance, manufacturing risk, and market access, making process development less a technical exercise and more a strategic business imperative that determines whether an API reaches clinic on time, within budget, and with sustainable competitive advantage.
Early Decisions Shape Future Outcomes
Many of the challenges that emerge during late-stage development originate much earlier.
A synthesis route selected to meet an immediate milestone may later create issues with yield, safety, cost, or manufacturability. Likewise, postponing impurity characterization, solid-form screening, or process safety assessments can introduce challenges that become much harder and more expensive to address as the program advances.
Successful programs reduce these risks by treating process development as a forward-looking activity rather than a checkpoint exercise, building future manufacturing requirements into decision-making from the outset. The reality is simple: the later a process issue is discovered, the greater its impact on timelines, budgets, and overall program success.
Speed Depends on the Process
Development speed is often measured by how quickly a molecule reaches the next milestone. The fastest programs are those that make the right process decisions early. By proactively addressing route selection, process optimization, impurity management, and safety, teams can reduce late-stage route changes, manufacturing investigations, and additional studies that often disrupt timelines. The result is a smoother path from IND-enabling studies to clinical manufacturing and beyond.
Process Understanding Drives Better Decisions
At its core, process development is about building process understanding. Chemistry provides the foundation for evaluating routes, controlling impurities, optimizing reactions, and planning for scale-up.
Understanding how process parameters affect product quality helps teams make informed decisions on performance, cost, and manufacturability. Approaches such as Quality by Design (QbD) and Design of Experiments (DoE) support data-driven development, resulting in more robust and reproducible processes.
Regulatory compliance has become inseparable from process design through ICH Q13 requirements for design space justification, critical process parameters established pre-filing, and PAT integration that enables real-time release testing—all of which must be architected during chemistry development to avoid regulatory holds and deviation management issues.
This increasing emphasis on process understanding also extends to the adoption of advanced monitoring and control strategies. Process Analytical Technology (PAT) adoption, driven by regulatory expectations for Real-Time Release Testing (RTRT) and continued process verification, requires early planning around sensor deployment, control strategy development, and data integration. Although implementation involves significant upfront investment, organizations can realize substantial benefits through reduced batch failures, accelerated product release timelines, improved process understanding, and greater regulatory agility.
in parallel, process analytical technology adoption—driven by regulatory mandates for RRLT and continuous verification—requires early sensor placement, control algorithm design, and data integration decisions that unlock $200K-$500K upfront investments recouped through 20-30% fewer batch failures, 1-week faster release timelines, and regulatory flexibility.
Supply Reliability Starts Early
Reliable supply starts long before manufacturing.
Supply chain resilience post-COVID demands that process routes be designed for multi-CMO redundancy and geographic diversification from the outset, with niche reagents (e.g., BINAP ligands experiencing 300% price spikes and 8-month shortages) requiring pre-qualified alternate routes filed with regulators before supplier crises strike.
Against this backdrop, decisions around route selection, raw materials, impurity control, and process safety influence how consistently a process performs as demand grows. By building robustness into the process early, sponsors can improve supply continuity, strengthen supply chain resilience, and support long-term manufacturing success.
Scale-Up Shouldn’t Be a Surprise
Scale-up is often where development assumptions are put to the test. As processes move from the lab to larger manufacturing environments, reaction behaviour and operating conditions can change significantly.
Scale-up challenges compound this urgency; reactions optimized at bench scale suffer 30-50% yield loss at MT scale due to mass transfer limitations, temperature gradients, and polymorphism shifts, while exothermic reactions risk runaway scenarios requiring forced simplification that cascades throughout the supply chain—poor scalability decisions alone cost significant equipment redesign and significant delays to market.
For this reason, addressing scalability, process safety, and manufacturing requirements early helps reduce uncertainty and enables a smoother transition to commercial-scale production. When process knowledge carries seamlessly into manufacturing, scale-up becomes a planned step rather than a potential setback.
A Better Path Forward
Sustainability and green chemistry are no longer optional; FDA/EMA now score process acceptability by E-factor metrics, large pharma contracts mandate waste reduction targets, and transition to Green Zone manufacturing requires inherently low-waste processes that often prove cost-advantageous through reduced solvent and disposal expenses.
Taken together, these considerations reinforce why process development is no longer just about preparing for manufacturing. It is about making smarter decisions that reduce costs, accelerate timelines, improve quality, strengthen supply reliability, and enable successful scale-up.
For today’s drug developers, the question is not whether process development matters. It is whether critical process decisions are being made early enough, and with enough insight, to support the success of the program tomorrow.
At Aragen, this starts with an integrated Process R&D model that brings together process chemists, analytical scientists, process safety experts, and scale-up teams from the outset. By connecting route scouting, process optimization, analytical development, process safety, and manufacturing readiness within a single workflow, we help preserve critical process knowledge, reduce development risk, and build scalable processes with commercialization in mind.
Planning a route finalization, IND submission, or scale-up transition? Connect with Aragen’s Process R&D experts to identify risks early and build a stronger path to commercialization.
